Trials / Completed
CompletedNCT06426823
The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Copenhagen · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with type 2 diabetes.
Detailed description
Each participant will attend four independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose/water): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2). MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines, pancreas, and bones.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Saline / placebo | NaCl (9 mg/ml) |
| OTHER | GIPR antagonist / study tool | GIP(3-30)NH2 |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2026-03-16
- Completion
- 2026-03-16
- First posted
- 2024-05-23
- Last updated
- 2026-03-18
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT06426823. Inclusion in this directory is not an endorsement.